DengiAll, which is Panacea Biotec's tetravalent live-attenuated vaccine, uses weakened strains of all four DENV serotypes. As a single-dose shot, it simplifies administration compared to other multi-dose vaccines.

India is advancing toward its first indigenous dengue vaccine, DengiAll, which has entered the final stage of testing. Developed by Panacea Biotec in collaboration with ICMR, this will be one of the world's first this single-shot vaccine targets all four dengue serotypes amid rising cases. Dengue is a viral infection caused by the dengue virus (DENV), which is transmitted to humans through the bite of infected mosquitoes. According to the World Health Organization (WHO), about half of the world's population is now at risk of dengue, with an estimated 100-400 million infections occurring each year. In 2024, India reported a total of 2,33,519 Dengue cases and 297 deaths, according to the National Centre for Disease Control.

Most people who get infected do not have symptoms. However, those who do, get better in 1-2 weeks.

Source: NDTV - February 28,2026